IP Library Granted Patent US 11,104,929
Granted Patent B2
US 11,104,929 · App. 16/915,927 · Granted Aug 31, 2021

Methods for producing ribosomally synthesized and posttranslationally modified peptides

Inventor: Eric Schmidt (Salt Lake City, UT)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
C12P21/02C07K14/195C12N1/20C12N1/205C12N9/48C12N15/52C12N15/74C12R2001/19C12Y501/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,929
App. No.
16/915,927
Granted
Aug 31, 2021
Kind
B2
Abstract

The disclosure provides recombinant cells and methods for producing a ribosomally synthesized and posttranslationally modified peptide (RiPP), as well as RiPP libraries and methods for producing RiPP libraries.

Claims (13)

1. A method for producing a ribosomally synthesized and posttranslationally modified peptide (RiPP), comprising culturing a recombinant cell in the presence of exogenous mevalonate, wherein the recombinant cell comprises a nucleic acid encoding a tru protein or a pat protein, and wherein the recombinant cell comprises a nucleic acid encoding a mev protein.

2. The method of claim 1 , wherein the recombinant cell expresses ERG12, ERG8, and MVD1.

3. The method of claim 1 , further comprising culturing the recombinant cell in the presence of an exogenous sulfide source.

4. The method of claim 3 , wherein the exogenous sulfide source comprises cysteine.

5. The method of claim 4 , wherein cysteine is provided at a concentration of 0.5-40 mM.

6. The method of claim 4 , wherein cysteine is provided at a concentration of 5-10 mM.

7. The method of claim 3 , wherein the exogenous sulfide source comprises cystine.

8. The method of claim 3 , wherein the exogenous sulfide source comprises hydrogen sulfide.

9. The method of claim 3 , wherein the exogenous sulfide source comprises sodium hydrosulfide.

10. The method of claim 1 , wherein the recombinant cell expresses a TruE variant.

11. The method of claim 1 , wherein the recombinant cell expresses a PatE variant.

12. The method of claim 1 , wherein the exogenous mevalonate is provided at a concentration of 5-40 mM.

13. The method of claim 1 , wherein the recombinant cell is Escherichia coli.

Assignments (1)
CONFIRMATORY LICENSE Recorded Oct 13, 2023
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065238/0057 →
Continuity (3)
Division 15770176
Provisional Application 62241583 · Oct 14, 2015
Related Publication 20210040529A1 · Feb 11, 2021